Last viewed: SRPT

Prices are updated after-hours

SRPT Nasdaq

Sarepta Therapeutics, Inc.

SRPT | $124.27 6.11% 5.75% 1.3M

|

Health Technology

(0.0% 1d) (-3.1% 1m) (1.6% 1y) (0.0% 2d) (6.1% 3d) (7.5% 7d) (163.7% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 11,668,953,000
http://www.sareptatherapeutics.com
Sec Filling | Patents | 743 employees

(US) Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

treatment

Drugs

AMONDYS 45 (casimersen)
Exondys 51 (eteplirsen)
Vyondys 53 (golodirsen)

add to watch list Paper trade email alert is off

Press-releases

Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
Published: 2024-04-24 (Crawled : 13:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M

|

Health Technology

| 6.09% | O: 0.46% H: 6.35% C: 5.6%
first therapeutics financial results

Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
Published: 2024-04-02 (Crawled : 06:00) - prnewswire.com
SRPT | $124.27 6.11% 5.75% 1.3M

|

Health Technology

| -2.83% | O: -0.15% H: 0.88% C: -0.53%
sales first biopharma

Sarepta Therapeutics to Present at Upcoming Investor Conferences - March 4, 2024
Published: 2024-03-04 (Crawled : 14:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M

|

Health Technology

| -3.44% | O: 0.0% H: 0.0% C: -3.72%
therapeutics

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
Published: 2024-02-28 (Crawled : 00:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M

|

Health Technology

| -12.21% | O: -0.28% H: 1.03% C: -2.58%
therapeutics financial results

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
Published: 2024-02-21 (Crawled : 15:30) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M

|

Health Technology

| -8.73% | O: -0.97% H: 1.06% C: -1.88%
therapeutics financial results

Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
Published: 2024-02-16 (Crawled : 15:00) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M

|

Health Technology

| -0.51% | O: 12.15% H: 2.1% C: -3.89%
fda therapeutics

Global Cell Penetrating Peptide Market Forecast Report to 2030, Featuring Biosynth, Creative Peptides, Cupid Peptide, Alta Bioscience, AnaSpec, Peptomyc, PolyPeptide, Bachem & Sarepta Therapeutics
Published: 2024-02-05 (Crawled : 11:00) - prnewswire.com
SRPT | $124.27 6.11% 5.75% 1.3M

|

Health Technology

| 2.46% | O: 0.12% H: 3.45% C: 3.4%
RVNC | $3.57 -2.46% -2.52% 1.8M

|

Health Technology

| -33.52% | O: -2.42% H: 1.05% C: -2.67%
report cell global therapeutics market

Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Published: 2024-01-29 (Crawled : 15:30) - biospace.com/
SRPT | $124.27 6.11% 5.75% 1.3M

|

Health Technology

| 4.65% | O: 0.06% H: 3.66% C: 1.43%
srp-5051 positive therapeutics duchenne study

Regenerative Medicine Market Worth $49.0 Billion | MarketsandMarkets™.
Published: 2024-01-26 (Crawled : 15:30) - prnewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K

|

Health Technology

| -9.57% | O: -0.27% H: 0.38% C: 0.07%
NVS | News | $98.35 1.1% 0.0% 2.2M

|

Health Technology

| -8.08% | O: 0.29% H: 0.15% C: -0.13%
SRPT | $124.27 6.11% 5.75% 1.3M

|

Health Technology

| 3.52% | O: 0.69% H: 0.12% C: -1.75%
GILD | $67.07 0.06% 0.06% 8.3M

|

Health Technology

| -16.39% | O: 0.0% H: 0.35% C: -0.88%
AMGN | News | $273.085 -0.17% -0.17% 2.5M

|

Health Technology

| -12.01% | O: 0.1% H: 0.47% C: 0.39%
market

REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
Published: 2024-01-16 (Crawled : 20:00) - prnewswire.com
SRPT | $124.27 6.11% 5.75% 1.3M

|

Health Technology

| 7.68% | O: -0.49% H: 3.17% C: 1.94%
RGNX | $16.05 0.94% 0.93% 350K

|

Health Technology

| 5.04% | O: -0.13% H: 0.0% C: -7.15%
CLSD | News P | $1.33 -2.92% -3.01% 200K

|

Health Technology

| -6.94% | O: 0.0% H: 0.0% C: -6.94%
rgx-314 aaviate positive treatment trial

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000950170-24-027498	4	2024-03-07	2024-03-04	Sell	F	1389	37725
0000950170-24-027497	4	2024-03-07	2024-03-05	Sell	S	3135	6621
0000950170-24-027495	4	2024-03-07	2024-03-04	Sell	F	1734	30093
0000950170-24-027494	4	2024-03-07	2024-03-04	Sell	F	237	26200
0000950170-24-027494	4	2024-03-07	2024-03-04	Sell	F	285	26437
0000950170-24-027496	4	2024-03-07	2024-03-04	Sell	F	1728	69494

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M

|

Consumer Services

BOF | $1.99 70.09% 41.21% 110M

|

ILAG | $0.51 6.03% 40.62% 1.7M

|

LICN | $0.941 68.04% 40.49% 15M

|

AMST | $3.31 65.5% 39.58% 70M

|

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M

|

Technology Services

WIMI | $1.15 58.53% 36.92% 19M

|

Technology Services

AIH | $0.45 12.5% 30.92% 320K

|

Health Services

MULN | News | $3.78 38.46% 27.78% 13M

|

RILY | $29.86 37.48% 27.26% 12M

|

Last 48 Hours Insiders Buying

RKT P 347 | $12.55 -0.63% 0.48% 1.7M

|

| 22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K

|

| 22:00
TGEN P 10000 | $0.685 39.71% 6.6K

|

| 20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K

|

| 15:30
RMCF | $3.54 0.28% 7.1K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar